Skip to main content
. Author manuscript; available in PMC: 2017 Jul 15.
Published in final edited form as: Clin Cancer Res. 2016 Mar 23;22(14):3419–3421. doi: 10.1158/1078-0432.CCR-16-0246

Figure 1.

Figure 1

Trispecific engineered proteins can enhance an immunologic synapse by a variable single-chain fragments (scFV) to a tumor-associated antigen (CD33) linked to a targeting and activating scFV (CD16) for NK cells combined with a second linker to IL-15. The addition of IL-15 can prolong NK cell survival, increase proliferation and activation resulting in NK cell secretion of cytotoxic mediators (left). These engineered proteins are generated by a linker between a scFV targeting a specific tumor associated antigen (CD33) and a CD16 scFVs that ligates NK cells. These are combined with a second linker to a cytokine (IL15) (right).